Is Artelo Biosciences Stock a good buy in 2025, according to Wall Street analysts?
The consensus among 2 Wall Street analysts covering (NASDAQ: ARTL) stock is to Strong Buy ARTL stock.
Out of 2 analysts, 1 (50%) are recommending ARTL as a Strong Buy, 1 (50%) are recommending ARTL as a Buy, 0 (0%) are recommending ARTL as a Hold, 0 (0%) are recommending ARTL as a Sell, and 0 (0%) are recommending ARTL as a Strong Sell.
What is ARTL's earnings growth forecast for 2025-2025?
(NASDAQ: ARTL) Artelo Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.35%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 22.38%.
Artelo Biosciences's earnings in 2025 is -$9,826,000.
In 2025, ARTL is forecast to generate -$6,037,099 in earnings, with the lowest earnings forecast at -$6,037,099 and the highest earnings forecast at -$6,037,099.
What is ARTL's forecast return on equity (ROE) for 2025-2027?
(NASDAQ: ARTL) forecast ROE is N/A, which is considered weak.
What is ARTL's Price Target?
According to 2 Wall Street analysts that have issued a 1 year ARTL price target, the average ARTL price target is $5.50, with the highest ARTL stock price forecast at $6.00 and the lowest ARTL stock price forecast at $5.00.
On average, Wall Street analysts predict that Artelo Biosciences's share price could reach $5.50 by Apr 28, 2026. The average Artelo Biosciences stock price prediction forecasts a potential upside of 444.55% from the current ARTL share price of $1.01.
What is ARTL's Earnings Per Share (EPS) forecast for 2025-2025?
(NASDAQ: ARTL) Artelo Biosciences's current Earnings Per Share (EPS) is -$3.05. In 2025, ARTL's EPS is forecast to hit -$1.84 (min: -$1.84, max: -$1.84).
What is ARTL's forecast return on assets (ROA) for 2025-2027?
(NASDAQ: ARTL) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 23.59%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.